Alpha-1 Adrenoceptor Antagonist Design for BPH Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for benign prostatic hyperplasia (BPH) do not adequately address the need for effective, non-surgical methods to shrink or prevent prostate enlargement, particularly in terms of alpha-1 adrenoceptor-mediated conditions, which affect urine flow and bladder function.
Innovation Solution
Administration of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-benzoic acid or its pharmaceutically acceptable salts, which act as alpha-1 adrenoceptor antagonists, either alone or in combination with other active agents, to relax prostate smooth muscle and improve urine flow.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing alpha-1 adrenoceptor antagonists are used to treat BPH, then prostate smooth muscle relaxation and urine flow improvement are achieved, but central nervous system side effects may occur due to blood-brain barrier penetration
Solution Approach 1:
The patent applies local quality by designing the compound to have selective distribution and action - it acts on peripheral alpha-1 adrenoceptors in the prostate while avoiding penetration into the central nervous system. The molecular structure is specifically engineered to exclude blood-brain barrier penetration, creating a localized therapeutic effect at the target site without systemic CNS exposure.
Solution Approach 2:
The patent uses the blood-brain barrier as a selective intermediary that naturally prevents the compound from reaching the central nervous system. By designing the molecule with specific physicochemical properties, the blood-brain barrier acts as a protective intermediary that allows peripheral therapeutic action while blocking harmful central nervous system exposure.
2Object-affected harmful factors
If prostate enlargement is treated medically rather than surgically, then patient morbidity and surgical risks are reduced, but treatment efficacy may be insufficient compared to surgical intervention
Solution Approach 1:
The patent applies parameter changes by optimizing the chemical structure, potency, and pharmacokinetic parameters of the alpha-1 adrenoceptor antagonist. The compound is designed with enhanced binding affinity and selective pharmacological parameters that maximize therapeutic effectiveness while maintaining the non-surgical treatment advantage. This includes optimizing lipophilicity, molecular weight, and receptor binding characteristics.
Data Source
AI summary
Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions.